J&J’s stel­lar prostate can­cer da­ta sig­nals the like­li­hood of a broad­er mar­ket ap­proval, as Pfiz­er ri­val strug­gles

CHICA­GO — J&J will be look­ing to ex­pand its block­buster mar­ket for Zyti­ga (abi­raterone) af­ter post­ing stel­lar da­ta at AS­CO show­ing that the drug com­bined with stan­dard hor­mone ther­a­py reg­is­tered a ma­jor im­prove­ment in pro­gres­sion-free sur­vival among new­ly di­ag­nosed pa­tients with metasta­t­ic prostate can­cer.

The LAT­I­TUDE study da­ta demon­strat­ed that the com­bi­na­tion ther­a­py de­liv­ered an av­er­age stretch of 33 months with­out the dis­ease wors­en­ing, com­pared to 14.8 months for stan­dard hor­mone ther­a­py. Zyti­ga plus pred­nisone in com­bi­na­tion with ADT de­creased the risk of pro­gres­sion or death by 53% com­pared to place­bo plus ADT in pa­tients with mH­N­PC. And while over­all sur­vival was not reached yet for the Zyti­ga com­bo, the com­par­i­son arm came in at 34.7 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.